Universal coronavirus vaccine program: next-generation nucleic acid vaccine development
Official title: Administrative Core
Funded at Wistar Institute · NIH-11404993 · Data updated 2026-11-12
A patient-focused big-picture grant aims to create a broad coronavirus vaccine using new delivery methods to protect people from current and future COVID-related viruses.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wistar Institute NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | September 22, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $103,682 |
| NIH project number | 5P01AI165066-03 |
| Project ID | NIH-11404993 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals at risk for Coronavirus infections and those who would benefit from broad protection against multiple CoV strains.
✕Less likely to help
People without exposure risk or those who do not respond to vaccines may see no direct benefit.
What this research studies
This program brings together expert teams to develop a universal coronavirus vaccine that could protect against multiple existing and emerging strains. It focuses on delivering nucleic acid vaccines via advanced nanoparticles to improve effectiveness and accessibility. The Administrative Core coordinates the efforts, governance, and collaboration across institutions to keep the project on track and patient-centered. If successful, this work could translate into a single vaccine approach that reduces the need for multiple shots for different coronaviruses.
Why it matters
Potential benefit: If successful, it could lead to a single, broadly protective vaccine against many coronaviruses, potentially simplifying vaccination and reducing future outbreaks.
How similar studies have gone: Past coronavirus vaccine research has shown promise with targeted approaches, but a universal strategy remains a novel goal.
Where this research is happening
-
Wistar Institute
Philadelphia, United States Active
Researchers
- Principal investigator: Weiner, David B. — Wistar Institute
- Study coordinator: Weiner, David B.
Related research
Other NIH-funded projects on the same topics.
-
Immunomodulation to Fight Cancer Spread
A cancer-focused training opportunity to learn how tumors and the immune system interact during cancer spread and use that knowledge to develop new immunotherapies.
-
Broadly neutralizing nanobodies to improve HIV therapy
Researchers are developing tiny antibodies called nanobodies to target HIV in new ways that could make treatments easier and more effective for people living with HIV.
-
BEAT-HIV: a collaborative effort to cure HIV with immunotherapy
A multi-institution study is testing a combination immunotherapy approach to achieve long-term HIV remission or cure for people on ART.
-
Epitope-engineered stem cells to enable HIV cure with targeted CAR-T therapy
A patient-focused plan to use a person’s own stem cells, edited to resist HIV and paired with specialized CAR-T cells, to clear HIV reservoirs.
-
Comprehensive bioinformatics support for cancer research at a leading cancer center
A cancer center-wide bioinformatics program helps researchers analyze data, build reusable data resources, and apply computational methods to cancer studies.
-
Refocusing HIV antibodies to target parts that block many strains
This project tries a new vaccine approach to steer the immune system to make antibodies that can block many types of HIV for people at risk.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.